Skip to Content
Webinar Recording

Student Educational Talk – March 2025

Recorded on: March 26, 2025

 

Uncover the science behind targeting IDH mutations in low-grade glioma and how vorasidenib, a dual IDH1/IDH2 inhibitor, is shaping treatment strategies. Nicholas Distefano, PharmD, from the Hospital of the University of Pennsylvania Pharmacy, will break down the phase 3 INDIGO trial, exploring its design, key efficacy outcomes, and safety data in patients with residual or recurrent IDH-mutant low-grade glioma. Learn what these findings mean for the future of neuro-oncology and how pharmacists play a vital role in managing patients on molecularly targeted therapies.